PT - JOURNAL ARTICLE AU - Zahra Raisi-Estabragh AU - Celeste McCracken AU - Maddalena Ardissino AU - Mae S. Bethell AU - Jackie Cooper AU - Cyrus Cooper AU - Nicholas C. Harvey AU - Steffen E. Petersen TI - NON-WHITE ETHNICITY, MALE SEX, AND HIGHER BODY MASS INDEX, BUT NOT MEDICATIONS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ARE ASSOCIATED WITH CORONAVIRUS DISEASE 2019 (COVID-19) HOSPITALISATION: REVIEW OF THE FIRST 669 CASES FROM THE UK BIOBANK AID - 10.1101/2020.05.10.20096925 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.10.20096925 4099 - http://medrxiv.org/content/early/2020/05/15/2020.05.10.20096925.short 4100 - http://medrxiv.org/content/early/2020/05/15/2020.05.10.20096925.full AB - Background Cardiometabolic morbidity and medications, specifically Angiotensin Converting Enzyme inhibitors (ACEi) and Angiotensin Receptor Blockers (ARBs), have been linked with adverse outcomes from coronavirus disease 2019 (COVID-19). This study aims to investigate factors associated with COVID-19 positivity for the first 669 UK Biobank participants; compared with individuals who tested negative, and with the untested, presumed negative, rest of the population.Methods We studied 1,474 participants from the UK Biobank who had been tested for COVID-19. Given UK testing policy, this implies a hospital setting, suggesting at least moderate to severe symptoms. We considered the following exposures: age, sex, ethnicity, body mass index (BMI), diabetes, hypertension, hypercholesterolaemia, ACEi/ARB use, prior myocardial infarction (MI), and smoking. We undertook comparisons between: 1) COVID-19 positive and COVID-19 tested negative participants; and 2) COVID-19 tested positive and the remaining participants (tested negative plus untested, n=501,837). Logistic regression models were used to investigate univariate and mutually adjusted associations.Results Among participants tested for COVID-19, non-white ethnicity, male sex, and greater BMI were independently associated with COVID-19 positive result. Non-white ethnicity, male sex, greater BMI, diabetes, hypertension, prior MI, and smoking were independently associated with COVID-19 positivity compared to the remining cohort (test negatives plus untested). However, similar associations were observed when comparing those who tested negative for COVID-19 with the untested cohort; suggesting that these factors associate with general hospitalisation rather than specifically with COVID-19.Conclusions Among participants tested for COVID-19 with presumed moderate to severe symptoms in a hospital setting, non-white ethnicity, male sex, and higher BMI are associated with a positive result. Other cardiometabolic morbidities confer increased risk of hospitalisation, without specificity for COVID-19. Notably, ACE/ARB use did not associate with COVID-19 status.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialOBSERVATION STUDY, NOT APPLICABLEFunding StatementZRE is supported by a British Heart Foundation Clinical Research Training Fellowship (FS/17/81/33318). SEP acknowledges support from the Barts Biomedical Research Centre funded by the National Institute for Health Research (NIHR). NCH and CC acknowledge support from the UK Medical Research Council (MRC #405050259; #U105960371), NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton, and NIHR Oxford Biomedical Research Centre, University of Oxford.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis analysis has been performed using UK Biobank data under access application 2964. The UK Biobank is an open access research resource with data available to all bone fide researchers on formal request without preferential access or exclusivity.